Cargando…

Stimulation of soluble guanylate cyclase by vericiguat reduces skeletal muscle atrophy of mice following chemotherapy

Background: The chemotherapeutic doxorubicin (DOX) promotes severe skeletal muscle atrophy, which induces skeletal muscle weakness and fatigue. Soluble guanylate cyclase (sGC) contributes to a variety of pathophysiological processes, but whether it is involved in DOX-induced skeletal muscle atrophy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Bo-ang, Li, Yu-lin, Han, Hai-tao, Lu, Bin, Jia, Xu, Han, Lu, Ma, Wei-xuan, Zhu, Ping, Wang, Zhi-hao, Zhang, Wei, Zhong, Ming, Zhang, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894251/ https://www.ncbi.nlm.nih.gov/pubmed/36744261 http://dx.doi.org/10.3389/fphar.2023.1112123

Ejemplares similares

Soluble guanylate cyclase (sGC) stimulator vericiguat alleviates myocardial ischemia-reperfusion injury by improving microcirculation
por: Cai, Yun, et al.
Publicado: (2022)

Soluble Guanylate Cyclase Stimulator Vericiguat Enhances Long-Term Memory in Rats without Altering Cerebral Blood Volume
por: Nelissen, Ellis, et al.
Publicado: (2021)

Comparison of Soluble Guanylate Cyclase Stimulators and Activators in Models of Cardiovascular Disease Associated with Oxidative Stress
por: Costell, Melissa H., et al.
Publicado: (2012)

Soluble Guanylate Cyclase Stimulators in Heart Failure
por: Kansakar, Sajog, et al.
Publicado: (2021)

The Soluble Guanylate Cyclase Stimulator IWP-953 Increases Conventional Outflow Facility in Mouse Eyes
por: Ge, Pei, et al.
Publicado: (2016)

The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases
por: Correia, Susana S., et al.
Publicado: (2021)

Bibliometric study of soluble guanylate cyclase stimulators in cardiovascular research based on web of science from 1992 to 2021
por: Jia, Xiao-Yan, et al.
Publicado: (2022)

The discovery and characterization of novel soluble guanylate cyclase stimulators
por: Masferrer, Jaime L
Publicado: (2015)

Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies
por: Boettcher, Michael, et al.
Publicado: (2020)

Beneficial Metabolic Effects of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in a Mouse Diet-Induced Obesity Model
por: Schwartzkopf, Chad D., et al.
Publicado: (2022)

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
por: Lian, Tian-Yu, et al.
Publicado: (2017)

Activation mechanism of human soluble guanylate cyclase by stimulators and activators
por: Liu, Rui, et al.
Publicado: (2021)

Structural studies of soluble guanylate cyclase
por: Macdonald, Jane, et al.
Publicado: (2009)

Nitric oxide-independent stimulation of soluble guanylate cyclase attenuates pulmonary fibrosis
por: Evgenov, Oleg V, et al.
Publicado: (2011)

Stimulators and Activators of Soluble Guanylate Cyclase: Review and Potential Therapeutic Indications
por: Nossaman, Bobby, et al.
Publicado: (2012)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
por: Frey, Reiner, et al.
Publicado: (2013)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
por: Frey, Reiner, et al.
Publicado: (2013)

Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
por: Frey, Reiner, et al.
Publicado: (2013)

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study
por: Pieske, Burkert, et al.
Publicado: (2017)

Retrospection on the Role of Soluble Guanylate Cyclase in Parkinson's Disease
por: Ghanta, Mohankrishna, et al.
Publicado: (2017)

Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation
por: Wittenborn, Elizabeth C., et al.
Publicado: (2021)

The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
por: Schwabl, Philipp, et al.
Publicado: (2018)

Stimulation of soluble guanylate cyclase improves donor organ function in rat heart transplantation
por: Benke, Kálmán, et al.
Publicado: (2020)

Atrophy signaling pathways in respiratory and limb muscles of guinea pigs exposed to chronic cigarette smoke: role of soluble guanylate cyclase stimulation
por: Peinado, Víctor Ivo, et al.
Publicado: (2023)

Vasoprotection by heme oxygenase-1: interactions with soluble guanylate cyclase
por: Durante, William
Publicado: (2011)

Crystal Structures of the Catalytic Domain of Human Soluble Guanylate Cyclase
por: Allerston, Charles K., et al.
Publicado: (2013)

A new small molecule inhibitor of soluble guanylate cyclase
por: Mota, Filipa, et al.
Publicado: (2015)

Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
por: Witte, Jeannine, et al.
Publicado: (2018)

Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
por: Frey, Reiner, et al.
Publicado: (2009)

Stimulation of soluble guanylate cyclase accelerates renal recovery following relief of unilateral ureteral obstruction
por: Wang-Rosenke, Yingrui, et al.
Publicado: (2009)

Soluble guanylate cyclase stimulation reduces oxidative stress in experimental Chronic Obstructive Pulmonary Disease
por: Paul, Tanja, et al.
Publicado: (2018)

First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension
por: Spreemann, Till, et al.
Publicado: (2017)

Effects of soluble guanylate cyclase stimulator on renal function in ZSF-1 model of diabetic nephropathy
por: Hu, Lufei, et al.
Publicado: (2022)

Probing the Molecular Mechanism of Human Soluble Guanylate Cyclase Activation by NO in vitro and in vivo
por: Pan, Jie, et al.
Publicado: (2017)

Thrombospondin-1 is a universal inhibitor of soluble guanylate cyclase activation
por: Miller, Thomas W, et al.
Publicado: (2009)

Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow
por: Rogers, Natasha M., et al.
Publicado: (2014)

Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma
por: Buys, Emmanuel S., et al.
Publicado: (2014)

Structures of soluble guanylate cyclase: implications for regulatory mechanisms and drug development
por: Gileadi, Opher
Publicado: (2014)

Probing the Structural Dynamics of the Catalytic Domain of Human Soluble Guanylate Cyclase
por: Khalid, Rana Rehan, et al.
Publicado: (2020)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_js1p71tspjm8t0ce3354mgkfct